Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revvity Board Declares Quarterly Dividend By: Revvity via Business Wire October 26, 2023 at 16:15 PM EDT The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 9, 2024 to all shareholders of record at the close of business on January 19, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20231026949602/en/Contacts Media Relations: Chet Murray (781) 462-5126 chet.murray@revvity.com Investor Relations: Steve Willoughby steve.willoughby@revvity.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Revvity Board Declares Quarterly Dividend By: Revvity via Business Wire October 26, 2023 at 16:15 PM EDT The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 9, 2024 to all shareholders of record at the close of business on January 19, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20231026949602/en/Contacts Media Relations: Chet Murray (781) 462-5126 chet.murray@revvity.com Investor Relations: Steve Willoughby steve.willoughby@revvity.com
The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 9, 2024 to all shareholders of record at the close of business on January 19, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20231026949602/en/
Media Relations: Chet Murray (781) 462-5126 chet.murray@revvity.com Investor Relations: Steve Willoughby steve.willoughby@revvity.com